Health Care & Life Sciences » Biotechnology | Array BioPharma Inc.

Array BioPharma Inc. | Mutual Funds

Mutual Funds that own Array BioPharma Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Select Biotechnology Portfolio
8,012,649
3.77%
-914,800
1.36%
07/31/2018
Vanguard Small Cap Index Fund
5,298,251
2.49%
68,004
0.08%
07/31/2018
Vanguard Total Stock Market Index Fund
5,292,055
2.49%
6,026
0.01%
07/31/2018
Fidelity Growth Company Fund
5,290,459
2.49%
-28,706
0.17%
07/31/2018
iShares Russell 2000 ETF
4,279,423
2%
-2,286
0.14%
09/06/2018
SPDR S&P Biotech ETF
4,056,455
1.91%
10,437
1.08%
09/06/2018
FTIF SICAV - Franklin Biotechnology Discovery Fund
4,050,000
1.91%
76,400
2.71%
06/30/2018
Vanguard Strategic Equity Fund
3,120,614
1.47%
0
0.61%
06/30/2018
Vanguard Small Cap Growth Index Fund
3,026,034
1.42%
44,747
0.18%
07/31/2018
Vanguard Extended Market Index Fund
2,787,319
1.31%
33,800
0.06%
07/31/2018

About Array BioPharma

View Profile
Address
3200 Walnut Street
Boulder Colorado 80301
United States
Employees -
Website http://www.arraybiopharma.com
Updated 07/08/2019
Array BioPharma, Inc. engages in the research, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other high-burden diseases. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony Piscopio, K.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.